Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Phase 2, two cohort trial evaluating the addition of ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in subjects with Chronic Lymphocytic Leukemia (leukemia-cll/" >CLL), who are currently on treatment with ibrutinib, alacabrutinib or venetoclax.
This is a Phase 2 open label, two treatment cohort trial evaluating the addition of ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in participants with CLL, who fail to achieve MRD negativity, after a minimum 6-month treatment with ibrutinib, alacabrutinib or venetoclax.
Participants with Chronic Lymphocytic Leukemia (CLL) who have been on treatment for at least 6 months Minimal Residual Disease positive at screening Adequate organ system function as specified in the protocol Ability to follow protocol procedures.
Exclusion Criteria:
Participants receiving cancer therapy or any investigational drug within 21 days of Cycle 1, Day 1. Participants with a known histological transformation Active Hepatitis B or Hepatitis C.
